1. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial. Issue 5 (May 2021) Authors: Matasar, Matthew J; Capra, Marcelo; Özcan, Muhit; Lv, Fangfang; Li, Wei; Yañez, Eduardo; Sapunarova, Katya; Lin, Tongyu; Jin, Jie; Jurczak, Wojciech; Hamed, Aryan; Wang, Ming-Chung; Baker, Ross; Bondarenko, Igor; Zhang, Qingyuan; Feng, Jifeng; Geissler, Klaus; Lazaroiu, Mihaela; Saydam, Guray; Sz... Journal: Lancet oncology Issue: Volume 22:Issue 5(2021) Page Start: 678 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗